Bulgaria’s Sopharma 2013 net profit falls 17.8% Bulgarian drug maker Sopharma said its net profit dropped 17.8% to BGN 33.6 million in 2013. The company's revenue rose by 2.7% to BGN 216 million in 2013, Sopharma said in a preliminary report filed with the Bulgarian Stock Exchange on Thursday. Earnings per share inched down to BGN 0.26 in the period under review from BGN 0.32 in 2012.
Source: profit.bg (03.02.2014)

Some 1.7 mln shares of Bulgarian Rose-Sevtopolis trade on Sofia bourse A total of 1,689,440 shares of pharmaceuticals producer Bulgarian Rose-Sevtopolis, equal to a 14% stake in the company, traded on the Sofia bourse on Tuesday, stock exchange data showed. The shares changed hands in eight deals at an average price of BGN 1.83 apiece, Sofia stock exchange data indicated. The parties to the deals were not disclosed. The buyer of the 14% stake was the Bulgarian unit of Romanian pharmaceutical company Rompharm, which increased its holdings in Bulgarian Rose-Sevtopolis to 20%. Also on Tuesday Rompharm acquired 3.0% of Bulgarian drug producer Sopharma, raising its stake to 17.5%. Bourse data indicated that 4,236,843 Sopharma shares, equal to a 3.2% stake in the company, changed hands in a series of transactions on the Sofia bourse on Tuesday at an average price of BGN 4.249 apiece. Sopharma held 49.99% of Bulgarian Rose Sevtopolis as of December 31.
Source: Capital (05.02.2014)

InvestBulgaria Agency yesterday gave its traditional awards Investor of the Year . At an official ceremony were awarded 17 companies. Seven of the companies were awarded with traditional bull sculptures, made by sculptor Seyfetin Shekerov. These are : Montupe Ltd, Lem Bulgaria Ltd, Sopharma Jsc, Amilum Bulgaria Jsc, Fraport Twin Star Airport Management Jsc, Comverse Bulgaria Ltd, Fairplay Properties REIT. The winner of the award for overall activity is ABB Ltd , as the prize was handed over by Prime Minister Oresharski. Nine companies were honored with special plaques - Sikom and plant Balkantsink Jsc, Hronovski BG Ltd, Lemi Trafo Jsc, Optix Jsc, Aroma Jsc, Bulgaria Fluorite Ltd, Britos Ltd, Vkusna Yadka Ltd, Experian Bulgaria Jsc. The 17 winners were chosen among 50 nominations. Companies were evaluated based on seven criteria, including the number of open jobs, potential for future development, etc.
Source: Standart (06.02.2014)

Bulgarian drug maker Sopharma Jan-Feb sales fall 2.0% Bulgarian drug producer Sopharma reported on Wednesday a 2.0% increase in its sales in the January-February period. Domestic sales increased by 11% in the first two months of 2014, while exports went down by 1.0%, Sopharma said in a filing with the Sofia stock exchange. In February alone, Sopharma’s sales decreased by 1.0% on the year as domestic sales grew 20% and exports fell 6.0%.
Source: profit.bg (06.03.2014)

Bulgaria's Unipharm plans to pay EUR 0.05 per share in gross dividend Bulgarian drug maker Unipharm plans to pay a gross dividend of BGN 0.09 per share for 2013, it said on Tuesday. The company’s shareholders will vote the decision at a general meeting to be held on June 18, Unipharm said in a bourse filing. Unipharm will distribute as a dividend a total of BGN 540,000 of its BGN 728,000 profit, after allocating 10% of the profit or some BGN 72,800 as legal reserve, while the rest of it will be set aside for additional reserves. The drug maker distributed a gross dividend of BGN 0.05 per share for 2012.
Source: Capital (14.05.2014)

Drug maker Sopharma to absorb unit Bulgarian Rose-Sevtopolis Bulgarian drug producer Sopharma said it will absorb its subsidiary, pharmaceuticals producer Bulgarian Rose-Sevtopolis. The decision was put to the vote at a meeting of Sopharma’s board of directors that took place on June 16, Sopharma said on Monday in a bourse filing. Sopharma held a 49.99% stake in Bulgarian Rose-Sevtopolis as of March 31, according to the subsidiary’s latest financial report. Local brokerage Elana Trading has been selected as an investment intermediary for the merger, Sopharma said. The Bulgarian unit of Romanian pharmaceutical company Rompharm, which held 18.17% in Sopharma as at March 31, also controlled 20.22% in Bulgarian Rose-Sevtopolis at the end of March.
Source: investor.bg (18.06.2014)

Bulgaria's Sopharma Properties gives up cap hike plans Bulgarian real estate investment trust Sopharma Properties said it decided to abandon plans to raise its capital to BGN 16.9 million after failing to obtain the approval of the financial regulator. The Financial Supervision Commission last week declined to approve the company's revised prospectus for an initial public offering of 1,228,070 voting shares with a par value of BGN 1 and an issue price of BGN 2.85 each, Sopharma Properties said in a bourse filing. Following the regulator's decision, Sopharma Properties' board of directors decided on Monday to terminate the capital increase procedure, the company added. Currently, Sopharma Properties' capital is divided into 15,710,686 voting shares with a par value of BGN 1 each. The company is majority owned by local blue-chip drug maker Sopharma.
Source: investor.bg (23.07.2014)

Sopharma purchased new 400 thousand shares of Medica Sopharma acquired another 400,010 shares in the capital of Medica SA, the company reported. This happens a day after it purchased 500 thousand shares of the medical devices manufacturer. Thus after the transaction, Sopharma’s share in Medica increased to 23.2%. For the first nine months of 2014 Medica JSC reported a profit of BGN 1.7 million against BGN 1.1 million as to to 30 September 2013. The company's sales are BGN 13.9 million compared to BGN 14.2 million for the previous period. Since the beginning of 2014 shares of Sopharma rose by 1.27 percent to BGN 3.90 per share.
Source: profit.bg (07.11.2014)

Bulgarian drug producer Sopharma said it has been cleared by the country's financial regulator to absorb its subsidiary Bulgarian Rose-Sevtopolis. The Financial Supervision Commission (FSC) approved the merger deal on November 7, Sopharma said in a bourse filing. The two companies signed a deal on June 19 under which Bulgarian Rose-Sevtopolis, a pharmaceuticals producer, will merge with Sopharma. As a result, Bulgarian Rose-Sevtopolis will be wound up without liquidation. Sopharma held a 49.99% stake in Bulgarian Rose-Sevtopolis as of September 31, according to the subsidiary’s latest financial report. The Bulgarian unit of Romanian pharmaceutical company Rompharm, which held 18.17% in Sopharma as at March 31, also controlled 20.22% in Bulgarian Rose-Sevtopolis at the end of September.
Source: profit.bg (13.11.2014)